Session 148 - 12th CROI

Home

Session 148 Poster Abstracts
Fat Redistribution: Novel Therapies and Switch Studies
Thursday, 1:30 - 3:30 pm
Hall B

854	A Randomized Placebo Controlled Trial of Rosiglitazone for the Treatment of HIV Lipodystrophy Rodrigo Cavalcanti*, K Kain, S Shen, J Raboud, and S Walmsley Univ of Toronto, Canada
855	Effects of Recombinant Human Growth Hormone (r-hGH) on Fat Depletion and Plasma Lipids in HIV-1 Infected Patients With Lipodystrophy - A Randomised, Open-label Study Markus Bickel*¹, S Zangos¹, V Jacobi¹, T Lutz², F Goebel³, S Staszewski¹, and S Klauke⁴ ¹JW Goethe Univ, Frankfurt, Germany; ²GP Gruenburgweg, Frankfurt, Germany; ³Ludwig Maximilians Univ, Munich, Germany; and ⁴IFS, Frankfurt, Germany
856	Effects of TH9507, a Growth Hormone Releasing Factor Analog, on the Quality of Life of HIV-infected Patients with Abdominal Fat Accumulation Julian Falutz*^1,2, S Allas³, N Dragano⁵, J C Mamputu³, B Lussier³, T Abribat³, L Vachon³, and S Grinspoon^4,6 ¹Montreal Gen Hosp, Canada; ²McGill Univ Med Sch, Montreal, Canada; ³Theratechnologies Inc, Montreal, Canada; ⁴Massachusetts Gen Hosp, Boston, USA; ⁵Heinrich Heine Univ, Dusseldorf, Germany; and ⁶Harvard Med Sch, Boston, MA, USA
857	A Randomized Open Study Comparing the Effect of Reducing Stavudine Dose vs Switching to Tenofovir on Mitochondrial Function, Metabolic Parameters, and Subcutaneous Fat in HIV-infected Patients Receiving Antiretroviral Therapy Containing Stavudine A Milinkovic*, S Lopez, S Vidal, O Miro, X Fernandez, J Arnaiz, J Blanco, A Leon, M Larrousse, M Lonca, M Laguno, J Mallolas, J Gatell, and E Martinez Hosp Clin, Barcelona, Spain
858	AI424067: Improvement in Lipid Profiles after 12 Weeks of Switching to Atazanavir from Boosted or Unboosted Protease Inhibitors in Patients with No Previous PI Virologic Failure and Hyperlipidemia at Baseline Michael Sension*¹, B Grinsztejn², J Molina³, I Zavala⁴, F Antunes⁵, A Donnelly⁶, P Agarwal⁶, and E Ledesma⁶ ¹Comprehensive Care Ctr, Fort Lauderdale, FL, USA; ²Hosp Evandro Chagas, Rio de Janeiro, Brazil; ³Hosp St-Louis, Paris, France; ⁴Hosp Dr Angel Leano Consultorio de Infectiologica, Jalisco, Mexico; ⁵Hosp Santa Maria, Lisbon, Portugal; and ⁶Bristol-Myers Squibb, Wallingford, CT, USA
859	Comparison between Switching Therapy from Protease Inhibitors to a NNRTI and Lipid-lowering Therapy with Pravastatin or Bezafibrate for the Management of HAART-related Dyslipidemia L Calza, Roberto Manfredi*, and F Chiodo Univ of Bologna, Italy
860	Improvement of Subcutaneous Fat, Lipid Profile, and Parameters of Mitochondrial Toxicity in Patients with Peripheral Lipoatrophy when Stavudine Is Switched to Tenofovir. The LIPOTEST Study Esteban Ribera*, J Paradineiro, S Sauleda, E Garcia Arumi, S Luque, V Falco, X Serres, R Comet, M Crespo, A Andreu, R Marti, I Ocana, D Sureda, and A Pahissa Hosp Vall d'Hebron, Barcelona, Spain